失调
微生物群
生物
噬菌体疗法
噬菌体
粪便细菌疗法
微生物学
代谢组
原噬菌体
人病毒体
肠道菌群
移植
免疫学
基因组
艰难梭菌
大肠杆菌
生物信息学
医学
遗传学
外科
抗生素
基因
代谢组学
作者
Torben Sølbeck Rasmussen,Anna Kirstine Koefoed,Rasmus Riemer Jakobsen,Ling Deng,Josué L. Castro‐Mejía,Anders Brunse,Horst Neve,Finn K. Vogensen,Dennis Sandris Nielsen
出处
期刊:Fems Microbiology Reviews
[Oxford University Press]
日期:2020-06-04
卷期号:44 (4): 507-521
被引量:75
标识
DOI:10.1093/femsre/fuaa020
摘要
ABSTRACT Gut microbiome (GM) composition and function are linked to human health and disease, and routes for manipulating the GM have become an area of intense research. Due to its high treatment efficacy, the use of fecal microbiota transplantation (FMT) is generally accepted as a promising experimental treatment for patients suffering from GM imbalances (dysbiosis), e.g. caused by recurrent Clostridioides difficile infections (rCDI). Mounting evidence suggests that bacteriophages (phages) play a key role in successful FMT treatment by restoring the dysbiotic bacterial GM. As a refinement to FMT, removing the bacterial component of donor feces by sterile filtration, also referred to as fecal virome transplantation (FVT), decreases the risk of invasive infections caused by bacteria. However, eukaryotic viruses and prophage-encoded virulence factors remain a safety issue. Recent in vivo studies show how cascading effects are initiated when phage communities are transferred to the gut by e.g. FVT, which leads to changes in the GM composition, host metabolome, and improve host health such as alleviating symptoms of obesity and type-2-diabetes (T2D). In this review, we discuss the promises and limitations of FVT along with the perspectives of using FVT to treat various diseases associated with GM dysbiosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI